Poolbeg Pharma Gets FDA Feedback
Poolbeg Pharma receives FDA feedback on cancer therapy POLB 001, potentially impacting development timeline. This may affect the company's stock price.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.